Northwest & Ethical Investments L.P. Takes $3.53 Million Position in Kenvue Inc. $KVUE

Northwest & Ethical Investments L.P. purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 168,626 shares of the company’s stock, valued at approximately $3,529,000.

Several other institutional investors also recently bought and sold shares of the company. Evergreen Wealth Solutions LLC lifted its stake in shares of Kenvue by 2.6% in the 1st quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock worth $402,000 after acquiring an additional 432 shares during the period. AlphaCore Capital LLC raised its holdings in Kenvue by 9.9% during the second quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock worth $111,000 after purchasing an additional 476 shares in the last quarter. Empirical Finance LLC lifted its position in Kenvue by 1.8% in the second quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after purchasing an additional 491 shares during the period. Everett Harris & Co. CA boosted its holdings in Kenvue by 1.4% in the 1st quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock valued at $887,000 after purchasing an additional 500 shares in the last quarter. Finally, Proffitt & Goodson Inc. boosted its holdings in Kenvue by 8.2% in the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after purchasing an additional 517 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Up 1.1%

Kenvue stock opened at $17.22 on Thursday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The firm has a market capitalization of $32.98 billion, a price-to-earnings ratio of 22.95 and a beta of 0.71. The stock’s fifty day moving average is $16.10 and its two-hundred day moving average is $19.65. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is currently 110.67%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KVUE. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. Jefferies Financial Group dropped their price objective on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Bank of America reduced their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, October 8th. Redburn Partners set a $22.00 target price on shares of Kenvue in a research report on Friday, September 26th. Finally, Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.